PHARMAC seeks views on access criteria for COVID-19 treatments

14 June 2022 - PHARMAC is seeking feedback on access criteria for two new COVID-19 treatments – tixagevimab with cilgavimab ...

Read more →

CADTH launches consultations on proposals to enhance drug review processes

4 April 2022 - CADTH has launched consultations on a proposed process for non-sponsored reimbursement reviews and a streamlined process ...

Read more →

PHARMAC publishes experts’ advice and seeks views on access criteria for COVID-19 treatments

16 February 2022 - PHARMAC is releasing meeting records of its COVID-19 Treatments Advisory Group and seeking feedback on the patient ...

Read more →

PHARMAC proposing to widen access to funded medicines

14 February 2022 - PHARMAC has issued a consultation today on proposals to widen access to two medicines, rituximab and zoledronic ...

Read more →

Review of the National Medicines Policy – consultation on the draft closes 16 February 2022

2 February 2022 - Since August 2021, the Committee has heard from nearly 200 stakeholders through bilateral interviews and virtual group ...

Read more →

Consultation paper on proposal to introduce a cost recovered pathway for Medical Services Advisory Committee applications

 4 January 2022 - The Department of Health invites submissions in relation to a proposal to introduce a cost recovered ...

Read more →

PHARMAC publishes experts’ advice and seeks views on patient access criteria for COVID-19 treatments

22 December 2021 - PHARMAC is releasing the October meeting records of their COVID-19 clinical expert advisory group and seeking feedback ...

Read more →

FDA publishes discussion paper and seeks public input on 3D printing of medical devices at the point of care

10 December 2021 - Today, the U.S. FDA published a discussion paper regarding 3D printing medical devices at the point of ...

Read more →

Consumers to have more say on medicine access issues

7 September 2021 - Consumer involvement in Australia’s medicines choices has been further strengthened under a new strategic agreement Medicines ...

Read more →

Patient advocacy organisations and FDA drug approval: lessons from Aduhelm

23 July 2021 - In the wake of last month’s controversial FDA approval of Biogen’s Aduhelm, Alzheimer’s Association CEO Harry ...

Read more →

NICE feedback?

13 July 2021 - NICE is quite far along a NICE led process to review its methods and processes for ...

Read more →

CMS opens national coverage determination analysis on treatment for Alzheimer’s disease

12 July 2021 - Today, the Centers for Medicare & Medicaid Services is opening a National Coverage Determination analysis, a ...

Read more →

PHARMAC is seeking views on declining funding applications

29 June 2021 - PHARMAC is considering declining 97 inactive medicine funding applications.  ...

Read more →

Moving patient stories highlight opportunities to strengthen our health care systems for all Australians

24 June 2021 - It was an emotional evening among the nearly 200 in-person and online attendees at Parliament House last ...

Read more →

Efficient funding of chemotherapy review - submissions on discussion paper

18 June 2021 - The efficient funding of chemotherapy review discussion paper was released on 21 May 2021 to gain ...

Read more →